ABSTRACT
A human trial was carried out to assess the ileal and fecal survival of Lactobacillus casei DN-114 001 ingested in fermented milk. Survival rates were up to 51.2% in the ileum and 28.4% in the feces. The probiotic bacterium has the capacity to survive during its transit through the human gut.
The probiotic strain Lactobacillus casei DN-114 001 (CNCM number I-1518) reduces the frequency or the duration of episodes of acute diarrhea in young children (20, 21), increases the lactobacillus concentration in the gut microbiota of infants (10), and can modulate ex vivo production of proinflammatory cytokines in Crohn's disease (4). Using mouse models harboring human microbiota, our group recently established that this bacterial strain can initiate new protein synthesis during transit, suggesting that the bacterium is metabolically active (18, 19).
In the present study, a human trial was carried out to assess the survival of L. casei DN-114 001 by culture analysis of ileal and fecal samples from healthy subjects consuming fermented milk. The test product (supplied by Danone Vitapole, Palaiseau, France) consisted of yogurt cultures (Streptococcus thermophilus and Lactobacillus delbruekii subsp. bulgaricus) supplemented with a rifampin-resistant spontaneous variant of L. casei DN 114 001, here referred to as strain DN-114 001Rif. This stable variant was isolated according to previously described methods (14) and led to the same growth kinetics and organoleptic properties as the original strain.
Ten volunteers (eight males and two females) with a median age of 25.5 years (range, 22 to 38 years) were included in the study after giving their written consent and were remunerated for their participation in the trial. They had no history of gastrointestinal disorders, no antibiotic treatment during the 2 months preceding the trial, and no laxative treatment for the week prior to the study. During the whole investigation period, the only restriction with regard to diet was the exclusion of fermented dairy products. The study was approved by a local Institutional Ethics Committee (Comité Consultatif de Protection des Personnes dans la Recherche Biomédicale, Necker) and was conducted at Necker Hospital, Paris, France. A blind review of data was performed to identify major protocol deviation and to define intention-to-treat and per-protocol populations. In per-protocol population analysis, all patients who had failed to complete the whole study protocol were excluded. Discontinuous variables were compared using the Wilcoxon rank test. For multiplicity of significance testing in the main analysis, the homogeneity of the two groups was tested using the chi-square test. The confidence interval was calculated as 95% (two tailed). The significance level used was 5%.
The trial consisted of two distinct steps, with an 8-day washout period between steps. The first step corresponded to the ileal-survival study, while the second focused on the analysis of L. casei DN-114 001Rif fecal survival.
Design of the ileal-survival study.
Seven out of 10 volunteers consented to intestinal intubation, which was performed after a 7-day period during which fermented dairy products were excluded from the diet. Each subject was nasally intubated with a triple-lumen weighed tube (Marquat SA, Boissy-Saint Léger, France), and once the pylorus was passed, a bag placed at the distal end of the first lumen was inflated in order to hasten tube progression. When the bag had reached the cecum, as confirmed fluoroscopically, subjects were asked to stay in a semirecumbent position. The second lumen was used to sample the ileal contents 35 cm above the ileocecal junction, while the third lumen, 25 cm proximal to the aspiration port, was used for infusion of polyethylene glycol (PEG).
On the morning of the following day, an infusion of 10 g PEG 4000 in 154 mmol NaCl · liter−1 at 37°C was started at the rate of 2 ml · min−1. After 1 h of equilibration, fasting subjects ingested a standard meal (125 g mashed potatoes, 1 hard boiled egg, 30 g jam, 100 g bread, 30 g butter, 10 g sugar, 250 ml tea or coffee, and a portion of melted cheese) and 3 bottles (3 × 100 ml in a single dose) of fermented milk containing about 108 CFU · ml−1 of L. casei DN-114 001Rif and 106 spores per ml of thermoresistant Bacillus stearothermophilus (Merck, Darmstadt, Germany) as a transit marker (15). Since the tube failed to go below the jejunum level in three volunteers, only four subjects were subsequently analyzed (the ileal per-protocol population). The ileal contents were continuously collected on ice by manual aspiration, with the aim of collecting as much fluid as possible over the 8 h following ingestion of the meal. The aspirated samples were pooled into 1-h aliquots, which were processed immediately for bacterial analysis. The remaining fluids were stored at −20°C for subsequent measurement of the PEG concentrations by means of turbidimetry (11), making it possible to calculate the population of bacteria transiting over time (22). For bacterial enumeration, 10-fold serial dilutions of homogenized ileal fluids were prepared, and each dilution was plated on Man-Rogosa-Sharpe agar medium containing 100 μg · ml−1 rifampin. The plates were incubated anaerobically at 37°C for 2 days before L. casei DN-114 001Rif CFU were counted. B. stearothermophilus spores were germinated and enumerated as previously reported (6).
Design of the fecal-survival study.
After a 7-day period during which fermented dairy products were excluded from the diet, the 10 initial volunteers were enrolled in the second step of the trial (the fecal intention-to-treat population). No L. casei DN-114 001Rif bacteria could be recovered from stools at the end of this washout period.
Each volunteer was asked to consume three bottles (3 × 100 ml) of the test product daily (1 bottle at each meal) for an 8-day period. As for the first step of the trial, 108 spores of B. stearothermophilus were added to each dose of the test product for the last 3 days of consumption. Stools were collected twice during the ingestion period (the fourth and eighth days) and twice after completion of intake of the test product (the third and seventh days after consumption ceased). The stool samples were processed within 30 min for bacterial enumeration according to the method described for ileal samples. Survival was calculated for samples obtained at the end of the consumption period, at which time full data were available for only six volunteers (four volunteers had missing or invalid data).
L. casei recovery from ileal fluid.
A peak in the population of L. casei DN-114 001Rif was observed in the ileal fluid during the 3 hours after volunteers consumed the test meal and the single dose of fermented milk (Fig. 1). In contrast, the transit marker persisted longer, reaching a plateau from 2 to 6 h after ingestion. The highest concentration of L. casei DN-114 001Rif detected in this compartment represented 10 to 100 times more bacteria than the resident microbiota (3), and it largely exceeded the concentration of probiotics that was previously suggested by some authors for the recovery of a clinical effect (at least 6 log10 CFU · ml−1 in the small bowel, according to Marteau et al. (15). Based on PEG measurements (Table 1), the total recovery of L. casei DN-114 001Rif in the ileum over the entire 8-hour period was estimated at 9.2 ± 0.5 log10 CFU, corresponding to around 3.6% of the total ingested quantity.
Transit of L. casei (solid line) and spores (dashed line) in the ileal lumens of four volunteers after ingestion of a meal with 300 ml of fermented milk containing L. casei (10.9 ± 0.5 log10 CFU per meal) and spores (8.4 ± 0.5 log10 CFU per meal). The results are presented as the number of bacteria transiting over time (mean plus standard error of the mean; n = 4). The percentages indicated at the different collection times correspond to L. casei apparent survival based on the ratio between the L. casei organisms and the spores (Table 2 shows the calculation method). When the percentage is not indicated, it is below 0.1%.
Bacterial recovery from ileal fluid collected during 8 h following ingestion of a standard meal and 300 ml of the test producta
The apparent survival of L. casei DN-114 001Rif was greater during the first 2 h of collection (51.2% to 10.0%) than what had been previously reported for other lactobacilli in the ileum (e.g., 0.5% for Lactobacillus fermentum KLD [24]; 1.5% for a commercial strain of Lactobacillus acidophilus [16]) or in the small intestine (e.g., 7% and 11.8% for Lactobacillus plantarum NCIMB 8826 [24] and for Lactobacillus salivarius UCC118 [5], respectively).
L. casei survival in stools.
In the stool-survival step of the trial, fermented-milk intake was continued long enough for L. casei to reach a steady state. Indeed, a plateau of about 7.6 log10 CFU · g−1 of stool was observed from 4 to 7 days following the fermented-milk consumption, while this level decreased rapidly after discontinuation (data not shown). The fecal concentrations of L. casei DN-114 001Rif reported here are substantially higher than the concentration of L. casei strain Shirota, estimated at 7 log10 CFU · g−1 of feces with a similar inoculum (25), suggesting lower survival abilities of the latter strain. The fecal population of L. casei DN-114 001Rif, corresponding to about 0.1% of the autochthonous microbiota, may be a key factor in its probiotic activities (3, 15), since it has been demonstrated that probiotic transit can be associated with transient variations of the total population of lactobacilli, enterococci, or bifidobacteria in the microbiota (5, 13, 23), as well as with fluctuations such as beta glucuronidase activity or short-chain fatty acid concentrations (9, 13, 23).
The apparent L. casei DN-114 001Rif survival was approximately 28.4% in the feces (Table 2). The difference between apparent survival rates observed in the ileum and in the feces might be related to the ileal sampling procedure. Indeed, we suspect that secretions, such as bile or defensins (8), could have affected the survival of L. casei DN-114 001Rif during the 1-h period separating the beginning of sampling and sample quantification. The apparently higher fecal survival could also be explained by Lactobacillus multiplication in the colon, as previously suggested (1, 12). Since the consumption protocols were different for ileal (300 ml once) and fecal (100 ml three times a day for 8 days) studies, a cumulative effect could be considered in the fecal experimentation. According to several studies, some Lactobacillus strains may attach transiently to the ileal mucosa (2, 17). Thus, a longer stay by lactobacilli consumed during the previous days could account for the apparently higher survival rate measured in the feces.
Bacterial recovery from fecal samples collected on day 7 of the experimenta
Conclusions.
The present trial led us to conclude that L. casei DN-114 001Rif survives well during gastrointestinal transit. In the ileum, the high population level of L. casei DN-114 001Rif might be compatible with a probiotic effect. In the feces, it corresponded to the subdominant population (3).
The questions as to whether L. casei DN-114 001 is metabolically active and which functions are specifically activated in the human gut still remain to be answered in order to understand the digestive tract adaptation and mechanisms of action of this probiotic.
ACKNOWLEDGMENTS
This work was supported in part by VITAPOLE, Danone, France.
FOOTNOTES
- Received 29 March 2006.
- Accepted 9 May 2006.
- Copyright © 2006 American Society for Microbiology
